SLAS

ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones

Retrieved on: 
Monday, April 1, 2024
University, Automation, Gene, Drug discovery, Cell Press, DNA, Artificial intelligence, SLAS, Society, Laboratory, CRISPR, Cell

TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.

Key Points: 
  • TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.
  • The new approach allows for not only faster drug screening, but also opens the door to use a host of new morphology-driven phenotypes in drug discovery campaigns.
  • In December, the company was also profiled in a special edition of Cell Press highlighting the emerging uses of AI in drug discovery screening.
  • "Our biopharma customers are looking to integrate new technologies to expand their phenotypic drug screening programs," said Janette Phi, Chief Business Officer at ThinkCyte.

ThinkCyte advances biopharma phenotypic drug discovery programs with publication and presentation milestones

Retrieved on: 
Monday, April 1, 2024
University, Automation, Gene, Drug discovery, Cell Press, DNA, Artificial intelligence, SLAS, Society, Laboratory, CRISPR, Cell

TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.

Key Points: 
  • TOKYO, April 1, 2024 /PRNewswire/ -- ThinkCyte today announced the publication of a paper in the March issue of Cell Reports Methods on a new method for high-throughput drug discovery.
  • The new approach allows for not only faster drug screening, but also opens the door to use a host of new morphology-driven phenotypes in drug discovery campaigns.
  • In December, the company was also profiled in a special edition of Cell Press highlighting the emerging uses of AI in drug discovery screening.
  • "Our biopharma customers are looking to integrate new technologies to expand their phenotypic drug screening programs," said Janette Phi, Chief Business Officer at ThinkCyte.

Society for Laboratory Automation and Screening (SLAS) Selects CytoTronics’ Pixel System for 2024 New Product Award

Retrieved on: 
Tuesday, March 5, 2024
Software, Research, Pharmaceutical, Hardware, Biometrics, Apps, Applications, Technology, Semiconductor, Health Technology, Science, Biotechnology, Health, Laboratory automation, Metabolism, Multimedia, Electrophysiology, SLAS, Epithelium, Conference, Society, Cell biology, Exhibition, ISSCR, Television

CytoTronics, Inc. , a pioneer of semiconductor-based platforms for discovery in cell biology, is pleased to announce that their Pixel ™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).

Key Points: 
  • CytoTronics, Inc. , a pioneer of semiconductor-based platforms for discovery in cell biology, is pleased to announce that their Pixel ™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).
  • Award selection was announced at the SLAS2024 International Conference and Exhibition in Boston, MA on February 6th, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240305158077/en/
    CytoTronics' Pixel™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).
  • Front-runners are interviewed on-site at the conference by a panel of industry veterans with deep expertise in laboratory automation and screening techniques to determine final award recipients.

Depixus wins SLAS2024 Ignite Award for MAGNA™ technology

Retrieved on: 
Monday, February 12, 2024
Health Technology, Technology, Radiology, Stem Cells, Pharmaceutical, Oncology, Biometrics, General Health, Genetics, Clinical Trials, Other Technology, Science, Biotechnology, Health, Research, Therapy, Laboratory automation, Multimedia, SLAS, Conference, Interactome, Society, RNA, Exhibition, Disease, Pharmaceutical industry

Interactomics pioneer Depixus has won the prestigious Society for Laboratory Automation and Screening (SLAS) Ignite Award at the society’s annual International Conference and Exhibition in Boston, MA, for their novel MAGNA™ technology.

Key Points: 
  • Interactomics pioneer Depixus has won the prestigious Society for Laboratory Automation and Screening (SLAS) Ignite Award at the society’s annual International Conference and Exhibition in Boston, MA, for their novel MAGNA™ technology.
  • The award coincides with the first showing of Depixus’ ground-breaking MAGNA One™ instrument at the conference.
  • View the full release here: https://www.businesswire.com/news/home/20240212670326/en/
    Depixus CEO Gordon Hamilton receives the SLAS2024 Ignite Award from judge Severine Tamas-Lhoustau, CEO of Novoptim.
  • Depixus CEO Gordon Hamilton says, “We’re thrilled to have won this year’s Ignite Award against such stiff competition and congratulate all the other finalists.

Parse Biosciences Partners with INTEGRA Biosciences for Automated Single Cell Workflows

Retrieved on: 
Tuesday, February 6, 2024
Software, Research, General Health, Professional Services, Technology, Infectious Diseases, Health Technology, Data Analytics, Science, Biotechnology, Stem Cells, Health, Other Science, Laboratory automation, Workflow, Cell, Transcriptome, Society, Laboratory, SLAS, Organization, Fine chemical

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has entered into an agreement with INTEGRA Biosciences to integrate the Assist Plus with built-in Parse Evercode™ single cell protocols.

Key Points: 
  • Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has entered into an agreement with INTEGRA Biosciences to integrate the Assist Plus with built-in Parse Evercode™ single cell protocols.
  • As part of the agreement, Parse will sell a bundled solution composed of Evercode single cell reagents and an application-enabled INTEGRA Assist Plus instrument directly to customers.
  • As part of the deal, Parse customers will be supported by both the Parse Biosciences and INTEGRA field service and sales teams.
  • The Parse Biosciences team will be presenting a poster on the efficiency gained by integrating the INTEGRA Assist Plus with the Evercode protocols at the Society for Laboratory Automation and Screening (SLAS) conference in Boston February 3-7.

CytoTronics Reveals Pixel System to Monitor Live Cell Function at an Unprecedented Scale for Cell Biology Applications

Retrieved on: 
Monday, February 5, 2024
Research, General Health, Pharmaceutical, Data Management, Technology, Semiconductor, Science, Biotechnology, Stem Cells, Other Technology, Other Science, Health, Epithelium, Laboratory automation, Cell biology, Electronics, Cell, B cell, Harvard University, Electrophysiology, USD, Exhibition, Data science, Medium (website), Drug discovery, Computer, Pixel, Metabolism, SLAS, Toxicology, Data collection, Television

Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, metabolism, and more while generating electrical ‘images’ with single-cell spatial resolution.

Key Points: 
  • Pixel assesses live cell function at single-cell resolution, allowing scientists to simultaneously monitor cell viability, morphology, electrophysiology, metabolism, and more while generating electrical ‘images’ with single-cell spatial resolution.
  • Pixel delivers simultaneous multi-modal, high-resolution readouts in 96- or 384-well plates, enabling cell monitoring and data collection at unprecedented scale.
  • It’s widely applicable for in vitro cell biology applications including drug discovery, from target validation to toxicology screening.”
    CytoTronics’ early-access program for Pixel Primo empowers cell biologists to unlock applications that were previously inaccessible.
  • The early-access program includes applications for endothelial and epithelial cells, cancer cell biology, mechanism of action/toxicology, stem cell biology, cardiac function, and neural function.

Propelling Diagnostics and Life Sciences Innovation from Early Phase Research to the Clinic: Revvity Showcases Cutting-Edge Solutions at SLAS2024

Retrieved on: 
Friday, February 2, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Health Technology, Transverse mode, Drug discovery, RNA interference, AAV, HCS, Drug development, PLX, Medicine, Genomics, CDX, CRISPR, G3, NGS, SLAS, GMP, Automation, Flow cytometry, Omics, Engineering, TB

As the landscape of medicine becomes more personalized, Revvity aims to provide high-value, cutting-edge solutions that foster scientific innovation and positively impact human health.

Key Points: 
  • As the landscape of medicine becomes more personalized, Revvity aims to provide high-value, cutting-edge solutions that foster scientific innovation and positively impact human health.
  • Its offerings are designed to provide differentiated capabilities, providing customers with tools needed for success in precision medicine and beyond.
  • Dr. Alan Fletcher, Revvity’s senior vice president, life sciences, stated, "We're here in our backyard showing how we're seamlessly bringing it all together, powering innovation from research to reality.
  • Revvity will be exhibiting a selection of its extensive range of life sciences and diagnostics products and services.

Opentrons® Unveils New Protocol Library and Generative AI Tools to Accelerate Lab Automation and Scale Scientific Research

Retrieved on: 
Thursday, February 1, 2024
Data Management, Technology, Health, Robotics, Other Science, Medical Devices, Research, Software, Artificial Intelligence, Genetics, Science, Cell biology, Ecosystem, Database, Exhibition, Disease, Genomics, Proteomics, Convention center, SLAS, Carnegie Mellon University, MIT, Genome, Conference, Synthetic biology, Consumer electronics

Opentrons Labworks, Inc ., a leader in lab automation and makers of accessible lab robotics, today announced the launch of its new protocol library, offering plug-and-play protocols for all Opentrons robots, including the Opentrons Flex™.

Key Points: 
  • Opentrons Labworks, Inc ., a leader in lab automation and makers of accessible lab robotics, today announced the launch of its new protocol library, offering plug-and-play protocols for all Opentrons robots, including the Opentrons Flex™.
  • Opentrons is building a first-of-its-kind ecosystem for simplifying and scaling lab automation, which comprises the protocol library along with generative AI tools for protocol development, coupled with stringent wet- and dry-lab verification processes.
  • The aim is to create the largest open-access set of robust liquid-handling automation protocols to streamline research across genomics, proteomics, cell biology, and synthetic biology.
  • “With hundreds of protocols already developed by our community of users and internal scientific team, the easily accessible protocol library and our latest innovation in generative-AI protocol development tools both mark a major milestone for scientists.

Deepcell Unveils Innovative AI-Powered Single Cell Morphology Data at Leading Scientific Meetings

Retrieved on: 
Thursday, February 1, 2024
Science, Software, Biotechnology, Research, Health, Artificial Intelligence, Data Management, Technology, SLAS, NVIDIA, Society, Laboratory automation, RNA-Seq, Intelligence, Cell biology, Conference

In addition, the company announced that its REM-I Platform is a finalist for the New Product Award at SLAS.

Key Points: 
  • In addition, the company announced that its REM-I Platform is a finalist for the New Product Award at SLAS.
  • “We look forward to sharing the tremendous progress we’ve made as a company with the scientific community at these meetings.
  • A year ago, we were presenting our first public datasets at AGBT and attending SLAS for the first time.
  • This year, we have the REM-I Platform in field testing, are presenting substantially more data, and look forward to the full commercialization of our instrument later this year,” said Maddison Masaeli, Ph.D., co-founder and chief executive officer at Deepcell.

SCIEX Expands High-Throughput Screening Solutions with Echo® MS+ system

Retrieved on: 
Friday, February 2, 2024
Technology, Research, Health Technology, Software, Biotechnology, Health, Pharmaceutical, Other Science, Science, AEMS, Multimedia, Risk, SLAS, OPI, Drug discovery, Online shopping

SCIEX, a global leader in life science analytical technologies, launches the Echo® MS+ system at SLAS 2024.

Key Points: 
  • SCIEX, a global leader in life science analytical technologies, launches the Echo® MS+ system at SLAS 2024.
  • The system couples proprietary Acoustic Ejection Mass Spectrometry technology and Open Port Interface (OPI) sampling with the capabilities of either the SCIEX ZenoTOF 7600 or Triple Quad 6500+ system to deliver precise qualitative and quantitative results, through an expanded panel of robust high-throughput screening workflows.
  • View the full release here: https://www.businesswire.com/news/home/20240201334134/en/
    The Echo® MS+ system unlocks enhanced high-throughput screening capability by bringing acoustic ejection mass spectrometry (AEMS) approaches to the SCIEX ZenoTOF 7600 system.
  • (Photo: Business Wire)
    The system addresses key challenges in high-throughput screening applications for drug discovery without the need for extensive method development.